"Suramin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
| Descriptor ID |
D013498
|
| MeSH Number(s) |
D02.455.426.559.847.638.555.750 D02.886.645.600.080.050.650.750 D04.615.638.555.750
|
| Concept/Terms |
Suramin Sodium- Suramin Sodium
- Sodium, Suramin
- Suramin, Hexasodium Salt
- Hexasodium Salt Suramin
- Salt Suramin, Hexasodium
|
Below are MeSH descriptors whose meaning is more general than "Suramin".
Below are MeSH descriptors whose meaning is more specific than "Suramin".
This graph shows the total number of publications written about "Suramin" by people in this website by year, and whether "Suramin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Suramin" by people in Profiles.
-
Diabetes-induced renal injury in rats is attenuated by suramin. J Pharmacol Exp Ther. 2012 Oct; 343(1):34-43.
-
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012 Jul; 70(1):49-56.
-
Activation of cholinergic receptors blocks non-adrenergic non-cholinergic contractions in the rat urinary bladder. Brain Res Bull. 2008 Dec 16; 77(6):420-6.
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
-
Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer. 2003 Mar 20; 104(2):167-74.
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
-
Cutting edge: purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism. J Immunol. 1999 Jul 15; 163(2):558-61.
-
Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am. 1999 May; 26(2):281-90.
-
Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. Clin Cancer Res. 1998 May; 4(5):1193-201.
-
Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate. J Biol Chem. 1997 Jun 20; 272(25):15891-7.